Privacy Policy
Signals Blog

Contributors

Categories

Stacey Johnson

Stacey Johnson is the editor of Signals and a contributor. For 25 years, Stacey has been providing strategic communications counsel to government, corporate, technology and health organizations. She began her career at the CTV Television Network and then moved to Hill & Knowlton Canada where she advised clients in a variety of industries and sectors. Stacey is the Vice President, Communications and Marketing for CCRM, a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies. She has a Master's degree in Public Relations. You can follow her on Twitter @msstaceyerin.

Posts by: Stacey


Right Turn: Visual analytics go viral (KT part 3)

Author: Stacey Johnson, 09/15/17

A fundamental (and obvious) truth about knowledge translation (KT) is that if you want your work to have impact, it needs to be engaging. A viral video reaches thousands or millions of people; a boring, complex, badly produced video reaches a handful of people (your family, closest friends and some colleagues. Maybe a curious ex.) […]

Right Turn: Why #ILookLikeAnEngineer is still around

Author: Stacey Johnson, 09/08/17

  I was on a Toronto subway this week and saw a woman wearing a button with #ILookLikeAnEngineer (see image right). Having blogged about this topic myself in 2015 and also having featured the blog of a female engineer sharing her thoughts, I was pleased to see this important campaign had jumped over to the […]

Right Turn: Teaching kids critical thinking skills

Author: Stacey Johnson, 09/01/17

I love kids. Their curiosity, passion and enthusiasm for life are infectious. With two teenagers at home, kids and school are very much on my mind right now. (I have a habit of blogging about back-to-school, as you can read here and here.) Because kids are so curious, they constantly explore the world around them. […]

Trying to get it right: a blog carnival about Right to Try

Author: Stacey Johnson, 08/29/17

The crux of Right to Try legislation, enacted by 37 U.S. states so far, is the premise that terminally ill patients should have access to experimental therapies, even if they haven’t been approved by the Food and Drug Administration yet. It sounds straight-forward right? My body, my risk, my decision. The U.S. already has measures […]